Electronic prescription service Surescripts says it is cutting off ReMy Health, used by Amazon's PillPack, limiting PillPack's access to patient histories
Christina Farr / CNBC :
Context & Ripple Effects
Amazon bought PillPack in 2018 to attack the prescription market dominated by CVS and Walgreens, but the acquisition has spent 2019 fighting over data rather than delivery. In July, Surescripts — itself facing an FTC lawsuit over its alleged e-prescription monopoly — accused its contractor ReMy Health of illegally passing data to PillPack, and weeks later CVS and Walgreens charged that PillPack was requesting prescription transfers without patients' consent.
Today's cutoff escalates that dispute from accusation to enforcement: Surescripts is severing ReMy Health's integration outright, which limits PillPack's access to the patient histories it needs to onboard and manage customers. For a pharmacy whose pitch was frictionless transfers nationwide, the data plumbing is now the battleground.
First-order effects
- ReMy Health loses its Surescripts e-prescribing integration immediately, and PillPack loses the Surescripts-mediated access to patient medication histories that ReMy Health's connection provided.
- PillPack's onboarding funnel narrows at exactly the moment CVS and Walgreens are contesting its transfer requests, forcing the Amazon unit to source patient histories through other channels.
Second-order effects
- CVS and Walgreens gain leverage in their consent fight with PillPack: with Surescripts enforcing, their claims that PillPack's data practices are improper now carry an operator's action behind them.
- Rivals with intact Surescripts access — and consolidating competitors like DivvyDose, acquired by UnitedHealth — can position themselves as the compliant alternative for patients switching pharmacies.
Third-order effects
- The episode shows whoever operates e-prescribing infrastructure can gate a new entrant's growth, which sharpens the stakes of the FTC's monopoly case against Surescripts and raises the odds of regulation over who controls prescription-data exchange.
- If data-gatekeeping becomes standard competitive practice, pharmacy entrants will need to build independent records pathways or partner with health systems, raising the capital bar for challenging incumbents.
The trend: US pharmacy competition is shifting from price and delivery toward control of prescription-data infrastructure, with the Surescripts-FTC fight deciding how open that plumbing must be.